Leerink Partnrs Forecasts Cencora’s Q3 Earnings (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Equities research analysts at Leerink Partnrs upped their Q3 2025 earnings estimates for Cencora in a report issued on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $3.89 for the quarter, up from their previous estimate of $3.87. The consensus estimate for Cencora’s current full-year earnings is $15.32 per share. Leerink Partnrs also issued estimates for Cencora’s FY2025 earnings at $15.52 EPS, FY2026 earnings at $17.17 EPS and FY2027 earnings at $19.01 EPS.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.51% and a return on equity of 266.62%.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. UBS Group lifted their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Wells Fargo & Company lifted their price target on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Price Performance

Shares of COR stock opened at $246.11 on Friday. Cencora has a 52-week low of $214.77 and a 52-week high of $262.26. The stock has a market cap of $47.57 billion, a PE ratio of 32.77, a PEG ratio of 1.59 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm’s 50 day moving average price is $239.08 and its two-hundred day moving average price is $236.51.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.89%. Cencora’s payout ratio is currently 29.29%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock worth $17,790,912 in the last ninety days. Insiders own 10.80% of the company’s stock.

Institutional Trading of Cencora

Several hedge funds and other institutional investors have recently modified their holdings of COR. Czech National Bank boosted its holdings in shares of Cencora by 12.6% during the 3rd quarter. Czech National Bank now owns 35,536 shares of the company’s stock worth $7,998,000 after buying an additional 3,990 shares during the period. Dynamic Advisor Solutions LLC boosted its holdings in Cencora by 15.2% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock valued at $262,000 after purchasing an additional 154 shares during the period. Tobam boosted its holdings in Cencora by 85.7% in the 3rd quarter. Tobam now owns 25,030 shares of the company’s stock valued at $5,634,000 after purchasing an additional 11,549 shares during the period. LVW Advisors LLC boosted its holdings in Cencora by 14.2% in the 3rd quarter. LVW Advisors LLC now owns 3,666 shares of the company’s stock valued at $825,000 after purchasing an additional 456 shares during the period. Finally, Iowa State Bank bought a new stake in Cencora in the 3rd quarter valued at about $1,390,000. Institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.